The Peter Attia Drive

Deep dives into longevity, health, and performance.

76 episodes processed

45 canon references4 curious5 novel

Episodes

# · Sep 7, 2026 · 01:16:50

Peter Attia explores blood pressure as one of the three primary drivers of atherosclerosis alongside high apoB and smoking. He explains why hypertension often goes undiagnosed, how to measure it accurately, and the damage it inflicts on the heart, brain, and kidneys. The episode covers lifestyle interventions including weight loss, exercise, and sodium reduction, and reviews pharmacologic options for those who need them.

1 canon3 editorial

# · Aug 31, 2026 · 1h 55m

Brian Grosberg

Brian Grosberg, a leading headache specialist, provides a comprehensive overview of primary headache disorders. He explains how to distinguish between the three major types—migraine, cluster, and tension headaches—which are often misdiagnosed. The discussion covers the strong genetic and hormonal drivers of migraine, its pathophysiology involving neurovascular changes and CGRP, and why the condition disproportionately affects women. Grosberg details a treatment landscape that has been transformed by CGRP-targeted drugs, neuromodulation devices, and the foundational importance of lifestyle modifications, while also addressing the severe unmet need due to a drastic shortage of specialists.

2 editorial

# · Aug 24, 2026 · 39:23

In this AMA, Peter Attia examines the liver's role as an early warning system for metabolic dysfunction. He explains how insulin resistance and visceral fat drive liver disease, why standard liver enzyme tests can be misleading, and which non-invasive tools (FIB‑4, FibroScan) provide better insight. The episode covers the spectrum from steatosis to fibrosis, the liver's capacity to heal, and effective interventions including weight loss, GLP‑1 agonists, and exercise, while debunking detox myths.

2 canon1 novel1 editorial

# · Aug 17, 2026 · 2h 17m

Linus Abrams

Peter Attia sits down with psychiatrist Dr. Linus Abrams to explore a holistic approach to mental health that goes beyond neurotransmitters. They discuss how hormones, metabolism, inflammation, and lifestyle factors shape mood and cognition. Key topics include distinguishing bipolar from unipolar depression, the evolutionary basis of depression and insomnia, the role of estrogen and progesterone in mood, thyroid dysfunction as a mimic of depression, and the promise and perils of ketamine and psychedelics. The conversation emphasizes integrating whole-body physiology into psychiatric care to move beyond mere symptom reduction.

2 editorial

# · Aug 10, 2026 · 53:22

In this solo episode, Peter Attia provides a structured framework for evaluating peptides, a class of compounds often marketed with exaggerated claims. He explains why peptides must be assessed individually, presents a five-question vetting tool and a three-tier evidence hierarchy, and applies them to BPC-157 and CJC-1295. He discusses the role of placebo in anecdotal reports, the importance of FDA approval, and the dangers of the gray market, aiming to help listeners navigate the hype and identify legitimate therapies.

1 canon3 editorial

# · Aug 3, 2026 · 02:25:14

Jim Otvos, Ph.D.

Jim Otvos, a biophysical chemist, explains how nuclear magnetic resonance (NMR) spectroscopy can measure lipoprotein particles directly, providing more clinically relevant information than standard cholesterol tests. He discusses why LDL particle number (LDL-P) and apolipoprotein B (apoB) are better predictors of cardiovascular risk than LDL cholesterol alone, and confronts the myth that large, 'fluffy' LDL particles are harmless. The conversation also covers how NMR can detect insulin resistance years before blood sugar rises, and introduces GlycA as a marker of chronic low-grade inflammation and the metabolic vulnerability index (MVX) as a predictor of frailty and mortality. Throughout, Otvos reflects on the resistance to adopting NMR diagnostics despite the rich data they yield from a single blood draw.

1 canon1 novel

# · Jul 27, 2026 · 01:04:00

Peter explores how basic science discoveries—often pursued out of pure curiosity—led to some of the most important medical breakthroughs of the past half century. He traces the stories behind GFP, statins, ACE inhibitors, PCR, CRISPR, and GLP-1 agonists, revealing how these came from jellyfish, fungi, snake venom, Yellowstone bacteria, salt flat microbes, and Gila monster venom. The episode makes a compelling case for continued investment in undirected, curiosity-driven research.

1 canon

# · Jul 20, 2026 · 19m 41s

In this solo AMA episode, Peter Attia examines the evidence linking environmental pollution to long-term health. He explains what environmental pollution includes, why it's difficult to study, and where it fits in the hierarchy of health priorities. He details the risks of air pollution, with a focus on PM2.5, and emphasizes the importance of indoor air quality. He also touches on the effects of noise and light pollution, and evaluates the science around EMFs and 5G, offering practical strategies to mitigate risks.

2 canon

# · Jul 13, 2026 · 01:56:48

Gayatri Devi, M.D.

Gayatri Devi, a neurologist specializing in memory disorders, explains that dementia is best understood as a spectrum of overlapping pathologies—Alzheimer's, vascular, Lewy body, and mixed—rather than a single disease. She discusses the role of neuroinflammation and viral infections in Alzheimer's progression and her approach to detecting subtle cognitive decline in high-functioning patients. The conversation covers the benefits and risks of anti-amyloid therapies like lecanemab and donanemab, including monitoring for ARIA. Dr. Devi also introduces her concept of menopause-related cognitive impairment, a reversible condition often mistaken for early dementia, and examines why women face a higher Alzheimer's risk. The episode highlights the shift toward personalized, multimodal dementia care and the promise of early detection and AI-assisted monitoring.

2 canon1 novel

# · Jul 6, 2026 · 1h 44m

Peter Attia

Peter Attia synthesizes 30+ hours of prior conversations with strength experts (Layne Norton, Andy Galpin, Mike Israetel) into a comprehensive guide to muscle and strength for longevity. The episode clarifies why muscle mass and strength are essential for both lifespan and healthspan, examines the mechanisms through which they protect health (metabolic function, inflammation, fall prevention, recovery from illness), and provides practical strategies for building and maintaining muscle across ages—from progressive overload principles to protein timing to creatine supplementation.

1 canon3 editorial

# · Jun 29, 2026 · 09:56

Peter Attia

Peter Attia examines new research on GLP-1 receptor agonists like Ozempic and Wegovy, with a focus on muscle loss. He explains why early alarms about high lean mass loss were partly driven by misinterpretation of DEXA scans, which count water loss as lean mass. The episode stresses that functional outcomes—strength and physical performance—matter more than body composition numbers alone. Peter also discusses early signals on retatrutide, a triple agonist that may preserve muscle better, and outlines practical steps to protect muscle and bone during weight loss, including protein intake and resistance training.

3 canon1 novel

# · Jun 22, 2026 · 1h 58m

Renato Tomioka, M.D., Ph.D.

Renato Tomioka, a leading reproductive medicine and gynecologic surgery expert, explores two frequently overlooked conditions affecting millions of women: endometriosis and adenomyosis. The episode covers how these conditions are diagnosed (including advances beyond traditional laparoscopy), why they often go undiagnosed for years, the decision-making process between hormonal therapy and surgery, how fertility preservation changes treatment strategy, and the profound effects of female age on egg quality and reproductive outcomes.

1 novel1 editorial

# · Jun 15, 2026 · 50m 23s

Peter Attia

Peter Attia examines breast cancer screening in depth, explaining why thousands of women still die despite available screening tools. He outlines a personalized framework for assessing individual risk based on genetics, family history, breast density, and lifestyle factors, then maps those risks to appropriate screening strategies—from standard mammography to supplemental MRI for high-risk women. The core argument: population-level guidelines are a starting point, but optimizing outcomes requires tailoring screening intensity to individual risk profiles.

# · Jun 8, 2026 · 1h 40m

Tom Dayspring, M.D.

In this highly technical episode, lipidologist Tom Dayspring joins Peter Attia to explore the intricate relationship between cholesterol metabolism and brain health. They discuss why the brain's cholesterol system operates almost entirely independently from the rest of the body, using apoE rather than apoB. Dayspring explains how APOE genotype—particularly the APOE4 allele—is the strongest genetic risk factor for late-onset Alzheimer's disease, influencing amyloid and tau pathology. The conversation also reviews what is known about the effects of statins, ezetimibe, omega-3 fatty acids, and CETP inhibitors on brain health. This episode provides a crucial framework for understanding the often misunderstood link between lipid-lowering therapies and neurodegenerative risk.

2 canon

# · Jun 1, 2026 · 54m 50s

Peter Attia explores the pharmacological landscape of sleep, discussing when and how sleep medications can be used effectively. He emphasizes that behavioral and environmental interventions must form the foundation of healthy sleep, and that drugs should only be considered after addressing underlying issues like sleep hygiene and circadian misalignment. The episode covers major classes of prescription sleep aids, including benzodiazepines, Z-drugs, and DORAs, their effects on sleep architecture, and their risks. Peter also highlights the appropriate use of sleep medications as short-term bridges during acute stress and the emerging potential of DORAs for Alzheimer's prevention in high-risk individuals. He reviews the limited evidence for common off-label supplements and stresses the importance of diagnosing the specific type of sleep problem before turning to pharmacology.

1 editorial

# · May 25, 2026 · 13:06

Peter Attia provides a framework for evaluating medications and supplements. He emphasizes that the first step is to clearly define the health problem, rather than jumping to a 'good' or 'bad' label. The intended purpose of an intervention determines how much evidence is needed and what risks are acceptable. He examines how baseline risk influences the true benefit of a therapy and why relative risk statistics can mislead.

4 canon

# · May 18, 2026 · 1h 2m 25s

Peter Attia

Peter Attia explores the practical application of genetic testing in health and disease, building a framework for understanding what genetic tests can and cannot reveal. He examines where genetic information provides genuine clinical value—particularly in inherited cardiac conditions and cancer syndromes—versus where it offers probabilistic risk signals without actionable insight. The episode emphasizes why directly measuring phenotype often matters more than inferring risk from DNA alone, and how to critically evaluate different types of genetic tests to avoid accumulating data without clarity.

1 editorial

# · May 11, 2026 · 07:35

Peter Attia provides an in-depth look at colorectal cancer screening, explaining why this cancer is so preventable and why getting screening right matters. He covers how CRC develops from polyps over a slow window, the unique preventive power of colonoscopy that can both find and remove precancerous growths, and clarifies the often-misunderstood NordICC trial results. The episode also addresses the rise in early-onset CRC, practical tips for colonoscopy preparation and quality assessment, and the risk-benefit calculus. Finally, he reviews non-invasive screening options like FIT and Cologuard, detailing what they can and cannot do.

1 canon

# · May 4, 2026 · 08:49

In this AMA episode, Peter Attia answers listener questions on key health topics, including how to use family history to assess disease risk, why cardiovascular disease remains under-treated despite effective prevention tools, and whether someone can be overweight yet metabolically healthy. He also outlines the minimum effective dose of strength training for health and the lifestyle interventions most likely to reduce dementia risk. Throughout, he emphasizes practical, evidence-based approaches to navigating real-world trade-offs in personal health management.